Rebamipide for use in prevention and treatment of Crohn’s disease Field of the Invention The present invention relates to rebamipide for use in a method of prevention and/or treatment of Crohn’s disease, in particular in a person suffering from increased intestinal permeability or in a person who is at risk of increased intestinal permeability. Crohn’s disease (CD) is an illness belonging to the group of inflammatory bowel diseases (IBD). It is a chronic multifactorial disorder, in which genetic, environmental, and microbial factors are involved. While the exact cause is unknown, it seems that the disease onset is triggered by environmental factors that perturb the mucosal barrier, alter the healthy balance of the gut microbiota, and abnormally stimulate gut immune responses. This leads to chronic inflammation of the intestine with typical symptoms such as diarrhea, weight loss, fatigue, rectal bleeding, and abdominal pain. The disorder may occur at any age although it usually starts in the teens and twenties. It is estimated to affect about 3 in 1,000 people in Europe and North America with a similar frequency in males and females. It most often affects the end of the small intestine and the beginning of the colon, but it may also affect any part of the GI tract from the mouth to the anus. Skip lesions and patchy inflammation are a typical finding in CD. At present there is no cure for Crohn’s disease and current treatment aims at reducing the inflammation that triggers the symptoms. Over the years, several classes of medications have been developed for the treatment of CD. The choice of the medication depends upon the location of inflammation, severity of disease, complications, and the response of the patient to medical treatment. Although mild disease can be treated with 5-aminosalicylates, either alone or in combination with antibiotics, many patients eventually require corticosteroids to control symptoms. They can help reduce inflammation and induce remission but their long-term use is associated with well known adverse effects, and thus are not recommended for maintenance therapy. Moreover, about a half of patients is unable to discontinue corticosteroid therapy without disease exacerbation. Immunosuppressants, such as thiopurines and methotrexate, are frequently prescribed for patients who are resistant to or dependent on corticosteroids; however, these drugs have a slow onset of action, severe adverse effects, and clinical remission rates of about 40%. Biological therapy using monoclonal antibodies against TNFa, such as infliximab (Remicade) and adalimumab (Humira), is used in patients unresponsive to conventional treatment with corticosteroids and immunosuppressants. Further option are antibodies against interleukins, such as ustekinumab (Stelara) that acts as antagonist of human IL-12 and IL-23, and those binding human integrins, such as vedolizumab (Entyvio) that targets integrin